Forty-six plasma samples from HIV-1 B subtype infected patients were analysed to validate our assay. Thirty-three patients had started a darunavir-containing salvage regimen and 13 patients had started a tipranavir-containing regimen. The samples were taken after treatment failure and before the initiation of new regimens.
The subjects’ characteristics are summarized in Table S1 (available as Supplementary data at JAC Online).